Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

May 31, 2019

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab emtansine

HER2-targeted antibody drug conjugate of trastuzumab and DM1

Trial Locations (1)

77030

Houston Methodist Hospital, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Jenny C. Chang, MD

OTHER